Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Vlado Perkovic, Meg Jardine, Ujjwala Vijapurkar & Gary Meininger. (2015) Renal effects of canagliflozin in type 2 diabetes mellitus. Current Medical Research and Opinion 31:12, pages 2219-2231.
Read now
Read now
Lawrence Blonde, Vincent Woo, Chantal Mathieu, Jacqueline Yee, Ujjwala Vijapurkar, William Canovatchel & Gary Meininger. (2015) Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials. Current Medical Research and Opinion 31:11, pages 1993-2000.
Read now
Read now
Articles from other publishers (12)
Tatsuhiko Urakami. (2023) Treatment strategy for children and adolescents with type 2 diabetes-based on ISPAD Clinical Practice Consensus Guidelines 2022. Clinical Pediatric Endocrinology 32:3, pages 125-136.
Crossref
Crossref
Haixia Chen, Yanan Jia & Qingwen Guo. 2020. Bioactive Natural Products. Bioactive Natural Products
199
220
.
Jasna Klen, Katja Goričar & Vita Dolžan. (2019) Genetic variability in sodium-glucose cotransporter 2 influences glycemic control and risk for diabetic retinopathy in type 2 diabetes patients. Journal of Medical Biochemistry 0:0.
Crossref
Crossref
Camila A. Pereira, Fernando S. Carneiro, Takayuki Matsumoto & Rita C. Tostes. (2018) Bonus Effects of Antidiabetic Drugs: Possible Beneficial Effects on Endothelial Dysfunction, Vascular Inflammation and Atherosclerosis. Basic & Clinical Pharmacology & Toxicology 123:5, pages 523-538.
Crossref
Crossref
Yoshishige Samukawa, Masakazu Haneda, Yutaka Seino, Takashi Sasaki, Atsushi Fukatsu, Yusuke Kubo, Yuri Sato & Soichi Sakai. (2018) Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment. Clinical Pharmacology in Drug Development 7:8, pages 820-828.
Crossref
Crossref
Eleni Xourgia, Athanasia Papazafiropoulou & Andreas Melidonis. (2018) Effects of antidiabetic drugs on epicardial fat. World Journal of Diabetes 9:9, pages 141-148.
Crossref
Crossref
Julio Rosenstock, Leonard Chuck, Manuel González-Ortiz, Kate Merton, Jagriti Craig, George Capuano & Rong Qiu. (2016) Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naïve Type 2 Diabetes. Diabetes Care 39:3, pages 353-362.
Crossref
Crossref
I. Dardi, T. Kouvatsos & S.A. Jabbour. (2016) SGLT2 inhibitors. Biochemical Pharmacology 101, pages 27-39.
Crossref
Crossref
Chantal Mathieu, Aurelian Emil Ranetti, Danshi Li, Ella Ekholm, William Cook, Boaz Hirshberg, Hungta Chen, Lars Hansen & Nayyar Iqbal. (2015) Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes. Diabetes Care 38:11, pages 2009-2017.
Crossref
Crossref
S. Matthaei, K. Bowering, K. Rohwedder, J. Sugg, S. Parikh & E. Johnsson. (2015) Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes. Diabetes, Obesity and Metabolism 17:11, pages 1075-1084.
Crossref
Crossref
Thorsten Siegmund & Edin Zelihic. (2015) Optimierung der glykämischen Kontrolle und des kardiovaskulären Risikos. CardioVasc 15:3, pages 54-58.
Crossref
Crossref
Deborah Hinnen. (2015) Short commentary on empagliflozin and its potential clinical impact. Therapeutic Advances in Endocrinology and Metabolism 6:2, pages 68-81.
Crossref
Crossref